Pasi Pohjanjousi
Orion Corporation (Finland)(FI)
Publications by Year
Research Areas
Prostate Cancer Treatment and Research, Heart Failure Treatment and Management, Radiopharmaceutical Chemistry and Applications, Cardiovascular Function and Risk Factors, Anesthesia and Sedative Agents
Most-Cited Works
- → Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure(2012)309 cited
- → Duration of the Haemodynamic Action of a 24-h Infusion of Levosimendan in Patients with Congestive Heart Failure(2006)142 cited
- → Effects of dexmedetomidine and propofol on patient-ventilator interaction in difficult-to-wean, mechanically ventilated patients: a prospective, open-label, randomised, multicentre study(2016)86 cited
- → Repetitive Dosing of Intravenous Levosimendan Improves Pulmonary Hemodynamics in Patients With Pulmonary Hypertension: Results of a Pilot Study(2008)82 cited
- → Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan(2004)68 cited
- → Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study(2015)61 cited
- → Population Pharmacokinetics of Dexmedetomidine in Critically Ill Patients(2013)46 cited
- → Introducing PIONEER: a project to harness big data in prostate cancer research(2020)39 cited
- → Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer(2023)23 cited
- → A multinational, drug utilization study to investigate the use of dexmedetomidine (Dexdor®) in clinical practice in the EU(2017)20 cited